Keywords: pharming, appeals, chmp, rhucin, rejection, leiden, netherlands-based
Pharming appeals CHMP Rhucin rejection
Article | 07 January 2008
Leiden, the Netherlands-based biotechnology firm Pharming NV has given written notice to the European Medicines Agency (EMEA) for re-examination of ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
